TY  - JOUR
AU  - Panić, Anastasija
AU  - Sudar-Milovanović, Emina
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10744
AB  - The liver is an organ in which many oxidative processes occur and represents an important target of oxidative stress (OxS). Under physiological conditions of normal mitochondrial homeostasis, hepatocytes effectively remove reactive oxygen species (ROS) by enabling metabolic adaptations and through the antioxidant defence system mechanisms. However, obesity-induced lipid accumulation in the hepatocytes causes significantly elevated production of ROS, reduces oxidative capacity, and increases oxidative stress (OxS). In men, compared with premenopausal women, the development of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in obesity are more prevalent, where oestradiol (E2), the most potent female sex steroid, is proposed as the main culprit. Exogenous oestradiol (E2) administration exerts beneficial effects on antioxidant properties, restores total plasma antioxidant capacity and decreases biomarkers of OxS in ovariectomized animal models. Thus, we hypothesized that E2 treatment in states of obesity could have beneficial effects against OxS in the obese male's liver. We assumed that E2 could directly affect the level of OxS by increasing the level/activity of the AOS enzymes, particularly SOD1, SOD2, GPx, and CAT, in obese males' livers. In addition, we assumed that the level of malondialdehyde (MDA) and protein carbonyl content (PCC) in obese males' livers would be reduced after E2 treatment as a result of E2 inhibitory effect on lipid peroxidation and protein oxidation, respectively. To test our hypothesis, we used the liver of a high-fat (HF) diet-fed male Wistar rats as an animal model of obesity, treated with E2 intraperitoneally (40 μg/kg). Preliminary results from this study support our hypothesis that E2 increases liver protein expression of AOS enzymes: SOD1, GPx, and CAT, in control and HF male rats compared with their respective controls. The protein level of SOD2 and CAT activity was increased in HF treated with E2 compared with non-treated HF rats. Moreover, as we expected, E2 administration significantly decreased the MDA level in both E2-treated groups compared to their controls, while the PCC level was significantly decreased in HF treated group compared with untreated HF rats. In conclusion, the preliminary results we obtained in this study indicate that E2 administration can effectively inhibit the OxS-related processes in the liver in HF diet-induced obesity by increasing AOS enzymes levels and CAT activity, and also by decreasing levels of MDA and PCC. A consequence of our hypothesis is that treatment with E2 may be an innovative way to improve obesity-related liver disease prevention and healing. © 2023 Elsevier Ltd
T2  - Medical Hypotheses
T1  - Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?
VL  - 174
SP  - 111049
DO  - 10.1016/j.mehy.2023.111049
ER  - 

@article{
author = "Panić, Anastasija and Sudar-Milovanović, Emina and Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Soskić, Sanja S. and Isenović, Esma R.",
year = "2023",
abstract = "The liver is an organ in which many oxidative processes occur and represents an important target of oxidative stress (OxS). Under physiological conditions of normal mitochondrial homeostasis, hepatocytes effectively remove reactive oxygen species (ROS) by enabling metabolic adaptations and through the antioxidant defence system mechanisms. However, obesity-induced lipid accumulation in the hepatocytes causes significantly elevated production of ROS, reduces oxidative capacity, and increases oxidative stress (OxS). In men, compared with premenopausal women, the development of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in obesity are more prevalent, where oestradiol (E2), the most potent female sex steroid, is proposed as the main culprit. Exogenous oestradiol (E2) administration exerts beneficial effects on antioxidant properties, restores total plasma antioxidant capacity and decreases biomarkers of OxS in ovariectomized animal models. Thus, we hypothesized that E2 treatment in states of obesity could have beneficial effects against OxS in the obese male's liver. We assumed that E2 could directly affect the level of OxS by increasing the level/activity of the AOS enzymes, particularly SOD1, SOD2, GPx, and CAT, in obese males' livers. In addition, we assumed that the level of malondialdehyde (MDA) and protein carbonyl content (PCC) in obese males' livers would be reduced after E2 treatment as a result of E2 inhibitory effect on lipid peroxidation and protein oxidation, respectively. To test our hypothesis, we used the liver of a high-fat (HF) diet-fed male Wistar rats as an animal model of obesity, treated with E2 intraperitoneally (40 μg/kg). Preliminary results from this study support our hypothesis that E2 increases liver protein expression of AOS enzymes: SOD1, GPx, and CAT, in control and HF male rats compared with their respective controls. The protein level of SOD2 and CAT activity was increased in HF treated with E2 compared with non-treated HF rats. Moreover, as we expected, E2 administration significantly decreased the MDA level in both E2-treated groups compared to their controls, while the PCC level was significantly decreased in HF treated group compared with untreated HF rats. In conclusion, the preliminary results we obtained in this study indicate that E2 administration can effectively inhibit the OxS-related processes in the liver in HF diet-induced obesity by increasing AOS enzymes levels and CAT activity, and also by decreasing levels of MDA and PCC. A consequence of our hypothesis is that treatment with E2 may be an innovative way to improve obesity-related liver disease prevention and healing. © 2023 Elsevier Ltd",
journal = "Medical Hypotheses",
title = "Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?",
volume = "174",
pages = "111049",
doi = "10.1016/j.mehy.2023.111049"
}

Panić, A., Sudar-Milovanović, E., Stanimirović, J., Obradović, M. M., Zafirović, S., Soskić, S. S.,& Isenović, E. R.. (2023). Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?. in Medical Hypotheses, 174, 111049.
https://doi.org/10.1016/j.mehy.2023.111049

Panić A, Sudar-Milovanović E, Stanimirović J, Obradović MM, Zafirović S, Soskić SS, Isenović ER. Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?. in Medical Hypotheses. 2023;174:111049.
doi:10.1016/j.mehy.2023.111049 .

Panić, Anastasija, Sudar-Milovanović, Emina, Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Soskić, Sanja S., Isenović, Esma R., "Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?" in Medical Hypotheses, 174 (2023):111049,
https://doi.org/10.1016/j.mehy.2023.111049 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Banjac, Katarina
AU  - Rizzo, Manfredi
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10756
AB  - Cardiometabolic diseases (CMD) are a direct consequence of modern living and contribute to the development of multisystem diseases such as cardiovascular diseases and diabetes mellitus (DM). CMD has reached epidemic proportions worldwide. A sodium pump (Na + /K + -ATPase) is found in most eukaryotic cells’ membrane and controls many essential cellular functions directly or indirectly. This ion transporter and its isoforms are important in the pathogenesis of some pathological processes, including CMD. The structure and function of Na + /K + -ATPase, its expression and distribution in tissues, and its interactions with known ligands such as cardiotonic steroids and other suspected endogenous regulators are discussed in this review. In addition, we reviewed recent literature data related to the involvement of Na + /K + -ATPase activity dysfunction in CMD, focusing on the Na + /K + -ATPase as a potential therapeutic target in CMD.
T2  - Frontiers in Endocrinology
T1  - The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases
VL  - 14
DO  - 10.3389/fendo.2023.1150171
ER  - 

@article{
author = "Obradović, Milan M. and Sudar-Milovanović, Emina and Gluvić, Zoran and Banjac, Katarina and Rizzo, Manfredi and Isenović, Esma R.",
year = "2023",
abstract = "Cardiometabolic diseases (CMD) are a direct consequence of modern living and contribute to the development of multisystem diseases such as cardiovascular diseases and diabetes mellitus (DM). CMD has reached epidemic proportions worldwide. A sodium pump (Na + /K + -ATPase) is found in most eukaryotic cells’ membrane and controls many essential cellular functions directly or indirectly. This ion transporter and its isoforms are important in the pathogenesis of some pathological processes, including CMD. The structure and function of Na + /K + -ATPase, its expression and distribution in tissues, and its interactions with known ligands such as cardiotonic steroids and other suspected endogenous regulators are discussed in this review. In addition, we reviewed recent literature data related to the involvement of Na + /K + -ATPase activity dysfunction in CMD, focusing on the Na + /K + -ATPase as a potential therapeutic target in CMD.",
journal = "Frontiers in Endocrinology",
title = "The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases",
volume = "14",
doi = "10.3389/fendo.2023.1150171"
}

Obradović, M. M., Sudar-Milovanović, E., Gluvić, Z., Banjac, K., Rizzo, M.,& Isenović, E. R.. (2023). The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. in Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1150171

Obradović MM, Sudar-Milovanović E, Gluvić Z, Banjac K, Rizzo M, Isenović ER. The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. in Frontiers in Endocrinology. 2023;14.
doi:10.3389/fendo.2023.1150171 .

Obradović, Milan M., Sudar-Milovanović, Emina, Gluvić, Zoran, Banjac, Katarina, Rizzo, Manfredi, Isenović, Esma R., "The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases" in Frontiers in Endocrinology, 14 (2023),
https://doi.org/10.3389/fendo.2023.1150171 . .

TY  - JOUR
AU  - Radaković-Ćosić, Jovana
AU  - Miković, Željko
AU  - Mandić-Rajčević, Stefan
AU  - Sudar-Milovanović, Emina
AU  - Stojsavljević, Aleksandar
AU  - Nikolić, Gorana
AU  - Radojičić, Ognjen
AU  - Perović, Milan
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10846
AB  - Infertility is a major global health issue, affecting approximately 9% of couples worldwide. Its prevalence increased steadily over the preceding decades, paralleling environmental and lifestyle changes. One assisted reproductive technique to overcome infertility is in vitro fertilization (IVF). The IVF procedure consists of several stages, one of which is controlled ovarian stimulation (COS) via various protocols allowing follicular recruitment and maturation in preparation for oocyte retrieval. Follicular fluid (FF) is the microenvironment in which oocytes develop during folliculogenesis, and FF information could be used to assess follicle and oocyte development and maturation stages. Nitric oxide (NO) is a component of FF that is being studied as a predictive factor of follicle maturation and egg quality and as a potential indicator of the success of COS during the IVF process. The hypothesis was that COS affects NO levels in the serum; more specifically, that NO levels in serum after COS correlate with NO levels in FF, based on literature data on the influence of female reproductive hormones on NO metabolism and data on the change in the hormonal milieu affected by COS use. Furthermore, it was hypothesized that NO levels in serum and FF after COS were related to the number of high-quality female reproductive cells obtained during IVF. Assuming that NO levels in serum after COS correlate with NO levels in FF, the central hypothesis of this study is that serum NO levels after COS could be a valuable predictor of oocyte quality and the number of high-quality female reproductive cells achieved by COS. As a result of the hypothesis, measuring NO could be a novel way to improve the efficiency of IVF treatment.
T2  - Medical Hypotheses
T1  - Does controlled ovarian stimulation during in vitro fertilization affect the level of nitric oxide a potential indicator of oocyte quality?
VL  - 174
SP  - 111061
DO  - 10.1016/j.mehy.2023.111061
ER  - 

@article{
author = "Radaković-Ćosić, Jovana and Miković, Željko and Mandić-Rajčević, Stefan and Sudar-Milovanović, Emina and Stojsavljević, Aleksandar and Nikolić, Gorana and Radojičić, Ognjen and Perović, Milan",
year = "2023",
abstract = "Infertility is a major global health issue, affecting approximately 9% of couples worldwide. Its prevalence increased steadily over the preceding decades, paralleling environmental and lifestyle changes. One assisted reproductive technique to overcome infertility is in vitro fertilization (IVF). The IVF procedure consists of several stages, one of which is controlled ovarian stimulation (COS) via various protocols allowing follicular recruitment and maturation in preparation for oocyte retrieval. Follicular fluid (FF) is the microenvironment in which oocytes develop during folliculogenesis, and FF information could be used to assess follicle and oocyte development and maturation stages. Nitric oxide (NO) is a component of FF that is being studied as a predictive factor of follicle maturation and egg quality and as a potential indicator of the success of COS during the IVF process. The hypothesis was that COS affects NO levels in the serum; more specifically, that NO levels in serum after COS correlate with NO levels in FF, based on literature data on the influence of female reproductive hormones on NO metabolism and data on the change in the hormonal milieu affected by COS use. Furthermore, it was hypothesized that NO levels in serum and FF after COS were related to the number of high-quality female reproductive cells obtained during IVF. Assuming that NO levels in serum after COS correlate with NO levels in FF, the central hypothesis of this study is that serum NO levels after COS could be a valuable predictor of oocyte quality and the number of high-quality female reproductive cells achieved by COS. As a result of the hypothesis, measuring NO could be a novel way to improve the efficiency of IVF treatment.",
journal = "Medical Hypotheses",
title = "Does controlled ovarian stimulation during in vitro fertilization affect the level of nitric oxide a potential indicator of oocyte quality?",
volume = "174",
pages = "111061",
doi = "10.1016/j.mehy.2023.111061"
}

Radaković-Ćosić, J., Miković, Ž., Mandić-Rajčević, S., Sudar-Milovanović, E., Stojsavljević, A., Nikolić, G., Radojičić, O.,& Perović, M.. (2023). Does controlled ovarian stimulation during in vitro fertilization affect the level of nitric oxide a potential indicator of oocyte quality?. in Medical Hypotheses, 174, 111061.
https://doi.org/10.1016/j.mehy.2023.111061

Radaković-Ćosić J, Miković Ž, Mandić-Rajčević S, Sudar-Milovanović E, Stojsavljević A, Nikolić G, Radojičić O, Perović M. Does controlled ovarian stimulation during in vitro fertilization affect the level of nitric oxide a potential indicator of oocyte quality?. in Medical Hypotheses. 2023;174:111061.
doi:10.1016/j.mehy.2023.111061 .

Radaković-Ćosić, Jovana, Miković, Željko, Mandić-Rajčević, Stefan, Sudar-Milovanović, Emina, Stojsavljević, Aleksandar, Nikolić, Gorana, Radojičić, Ognjen, Perović, Milan, "Does controlled ovarian stimulation during in vitro fertilization affect the level of nitric oxide a potential indicator of oocyte quality?" in Medical Hypotheses, 174 (2023):111061,
https://doi.org/10.1016/j.mehy.2023.111061 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Zafirović, Sonja
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Rizzo, Manfredi
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10409
AB  - Thyroid hormones (TH) have a significant impact on cellular oxidative metabolism. Besides that,they maintain vascular homeostasis by positive effects on endothelial and vascular smooth muscle cells. Subclinical(SCH) and clinical (CH) hypothyroidism influences target organs by changing their morphology andfunction and impaired blood and oxygen supply induced by accelerated atherosclerosis. The increased risk ofacceleration and extension of atherosclerosis in patients with SCH and CH could be explained by dyslipidemia,diastolic hypertension, increased arterial stiffness, endothelial dysfunction, and altered blood coagulation. Instabilityof atherosclerotic plaque in hypothyroidism could cause excessive activity of the elements of innateimmunity, which are characterized by the significant presence of macrophages in atherosclerotic plaques, increasednuclear factor kappa B (NFkB) expression, and elevated levels of tumor necrosis factor α (TNF-α) andmatrix metalloproteinase (MMP) 9, with reduced interstitial collagen; all of them together creates inflammationmilieu, resulting in plaque rupture. Optimal substitution by levothyroxine (LT4) restores biochemical euthyroidism.In postmenopausal women and elderly patients with hypothyroidism and associated vascularcomorbidity, excessive LT4 substitution could lead to atrial rhythm disorders and osteoporosis. Therefore, it isof interest to maintain thyroid-stimulating hormone (TSH) levels in the reference range, thus eliminating thedeleterious effects of lower or higher TSH levels on the cardiovascular system. This review summarizes the recentliterature on subclinical and clinical hypothyroidism and atherosclerotic cardiovascular disease and discussesthe effects of LT4 replacement therapy on restoring biochemical euthyroidism and atherosclerosis processes.
T2  - Current Pharmaceutical Design
T1  - Hypothyroidism and Risk of Cardiovascular Disease
VL  - 28
IS  - 25
SP  - 2065
EP  - 2072
DO  - 10.2174/1381612828666220620160516
ER  - 

@article{
author = "Gluvić, Zoran and Zafirović, Sonja and Obradović, Milan M. and Sudar-Milovanović, Emina and Rizzo, Manfredi and Isenović, Esma R.",
year = "2022",
abstract = "Thyroid hormones (TH) have a significant impact on cellular oxidative metabolism. Besides that,they maintain vascular homeostasis by positive effects on endothelial and vascular smooth muscle cells. Subclinical(SCH) and clinical (CH) hypothyroidism influences target organs by changing their morphology andfunction and impaired blood and oxygen supply induced by accelerated atherosclerosis. The increased risk ofacceleration and extension of atherosclerosis in patients with SCH and CH could be explained by dyslipidemia,diastolic hypertension, increased arterial stiffness, endothelial dysfunction, and altered blood coagulation. Instabilityof atherosclerotic plaque in hypothyroidism could cause excessive activity of the elements of innateimmunity, which are characterized by the significant presence of macrophages in atherosclerotic plaques, increasednuclear factor kappa B (NFkB) expression, and elevated levels of tumor necrosis factor α (TNF-α) andmatrix metalloproteinase (MMP) 9, with reduced interstitial collagen; all of them together creates inflammationmilieu, resulting in plaque rupture. Optimal substitution by levothyroxine (LT4) restores biochemical euthyroidism.In postmenopausal women and elderly patients with hypothyroidism and associated vascularcomorbidity, excessive LT4 substitution could lead to atrial rhythm disorders and osteoporosis. Therefore, it isof interest to maintain thyroid-stimulating hormone (TSH) levels in the reference range, thus eliminating thedeleterious effects of lower or higher TSH levels on the cardiovascular system. This review summarizes the recentliterature on subclinical and clinical hypothyroidism and atherosclerotic cardiovascular disease and discussesthe effects of LT4 replacement therapy on restoring biochemical euthyroidism and atherosclerosis processes.",
journal = "Current Pharmaceutical Design",
title = "Hypothyroidism and Risk of Cardiovascular Disease",
volume = "28",
number = "25",
pages = "2065-2072",
doi = "10.2174/1381612828666220620160516"
}

Gluvić, Z., Zafirović, S., Obradović, M. M., Sudar-Milovanović, E., Rizzo, M.,& Isenović, E. R.. (2022). Hypothyroidism and Risk of Cardiovascular Disease. in Current Pharmaceutical Design, 28(25), 2065-2072.
https://doi.org/10.2174/1381612828666220620160516

Gluvić Z, Zafirović S, Obradović MM, Sudar-Milovanović E, Rizzo M, Isenović ER. Hypothyroidism and Risk of Cardiovascular Disease. in Current Pharmaceutical Design. 2022;28(25):2065-2072.
doi:10.2174/1381612828666220620160516 .

Gluvić, Zoran, Zafirović, Sonja, Obradović, Milan M., Sudar-Milovanović, Emina, Rizzo, Manfredi, Isenović, Esma R., "Hypothyroidism and Risk of Cardiovascular Disease" in Current Pharmaceutical Design, 28, no. 25 (2022):2065-2072,
https://doi.org/10.2174/1381612828666220620160516 . .

TY  - JOUR
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10147
AB  - The essential amino acid tryptophan (Trp) undergoes catabolism through several pathways, producing biologically active metabolites that significantly impact physiological processes. The metabolic pathway responsible for the majority of Trp catabolism is the kynurenine synthesis pathway (KP). Serotonin and melatonin are among the most essential Trp pathways degradation products. It has emerged that a strong relationship exists between alterations in Trp metabolism and the onset and progression of atherosclerosis and diabetes. Atherosclerosis is a chronic inflammatory disease of the small and medium arteries wall caused by maladaptive local immune responses, which underpins several cardiovascular diseases (CVD). Systemic low-grade immune-mediated inflammation is implicated in atherosclerosis where pro-inflammatory cytokines, such as interferon-γ (IFN-γ), play a significant role. IFN-γ upregulates the enzyme indoleamine 2,3-dioxygenase (IDO), decreasing serum levels of the Trp and increasing metabolite levels of kynurenine. Increased IDO expression and activity could accelerate the atherosclerosis process. Therefore, activated IDO inhibition could offer possible treatment options regarding atherosclerosis management. Diabetes is a chronic metabolic disease characterized by hyperglycemia that, over time, leads to severe damage to the heart, blood vessels, eyes, kidneys, and peripheral nerves. Trp serum levels and lower activity of IDO were higher in future type 2 diabetes (T2DM) patients. This article reviews recent findings on the link between mammalian Trp metabolism and its role in atherosclerosis and diabetes and outlines the intervention strategies.
T2  - Current Medicinal Chemistry
T1  - Tryptophan Metabolism in Atherosclerosis and Diabetes
VL  - 29
IS  - 1
SP  - 99
EP  - 113
DO  - 10.2174/0929867328666210714153649
ER  - 

@article{
author = "Sudar-Milovanović, Emina and Gluvić, Zoran and Obradović, Milan M. and Zarić, Božidarka and Isenović, Esma R.",
year = "2022",
abstract = "The essential amino acid tryptophan (Trp) undergoes catabolism through several pathways, producing biologically active metabolites that significantly impact physiological processes. The metabolic pathway responsible for the majority of Trp catabolism is the kynurenine synthesis pathway (KP). Serotonin and melatonin are among the most essential Trp pathways degradation products. It has emerged that a strong relationship exists between alterations in Trp metabolism and the onset and progression of atherosclerosis and diabetes. Atherosclerosis is a chronic inflammatory disease of the small and medium arteries wall caused by maladaptive local immune responses, which underpins several cardiovascular diseases (CVD). Systemic low-grade immune-mediated inflammation is implicated in atherosclerosis where pro-inflammatory cytokines, such as interferon-γ (IFN-γ), play a significant role. IFN-γ upregulates the enzyme indoleamine 2,3-dioxygenase (IDO), decreasing serum levels of the Trp and increasing metabolite levels of kynurenine. Increased IDO expression and activity could accelerate the atherosclerosis process. Therefore, activated IDO inhibition could offer possible treatment options regarding atherosclerosis management. Diabetes is a chronic metabolic disease characterized by hyperglycemia that, over time, leads to severe damage to the heart, blood vessels, eyes, kidneys, and peripheral nerves. Trp serum levels and lower activity of IDO were higher in future type 2 diabetes (T2DM) patients. This article reviews recent findings on the link between mammalian Trp metabolism and its role in atherosclerosis and diabetes and outlines the intervention strategies.",
journal = "Current Medicinal Chemistry",
title = "Tryptophan Metabolism in Atherosclerosis and Diabetes",
volume = "29",
number = "1",
pages = "99-113",
doi = "10.2174/0929867328666210714153649"
}

Sudar-Milovanović, E., Gluvić, Z., Obradović, M. M., Zarić, B.,& Isenović, E. R.. (2022). Tryptophan Metabolism in Atherosclerosis and Diabetes. in Current Medicinal Chemistry, 29(1), 99-113.
https://doi.org/10.2174/0929867328666210714153649

Sudar-Milovanović E, Gluvić Z, Obradović MM, Zarić B, Isenović ER. Tryptophan Metabolism in Atherosclerosis and Diabetes. in Current Medicinal Chemistry. 2022;29(1):99-113.
doi:10.2174/0929867328666210714153649 .

Sudar-Milovanović, Emina, Gluvić, Zoran, Obradović, Milan M., Zarić, Božidarka, Isenović, Esma R., "Tryptophan Metabolism in Atherosclerosis and Diabetes" in Current Medicinal Chemistry, 29, no. 1 (2022):99-113,
https://doi.org/10.2174/0929867328666210714153649 . .

TY  - JOUR
AU  - Radovanović, Jelena
AU  - Antonijević, Biljana
AU  - Baralić, Katarina
AU  - Ćurčić, Marijana
AU  - Đukić-Ćosić, Danijela
AU  - Bulat, Zorica
AU  - Javorac, Dragana
AU  - Buha-Đorđević, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Sudar-Milovanović, Emina
AU  - Antonijević-Miljaković, Evica
AU  - Beloica, Miloš
AU  - Mandinić, Zoran
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10464
AB  - This study aimed to investigate the effect of 150 mg/L sodium fluoride (NaF) on redox status parameters and essential metals [copper (Cu), iron (Fe), and zinc (Zn)] in the blood, liver, kidney, brain, and spleen of Wistar rats and to determine the protective potential of selenium (Se) against fluoride (F-) toxicity. Male Wistar rats were randomly distributed in groups of five (n=5) receiving tap water (control) or water with NaF 150 mg/L, NaF 150 mg/L + Se 1.5 mg/L, and Se 1.5 mg/L solutions ad libitum for 28 days. Fluorides caused an imbalance in the redox and biometal (Cu, Fe, and Zn) status, leading to high superoxide anion (O2 .-) and malondialdehyde (MDA) levels in the blood and brain and a drop in superoxide dismutase (SOD1) activity in the liver and its increase in the brain and kidneys. Se given with NaF improved MDA, SOD1, and O2 .- in the blood, brain, and kidneys, while alone it decreased SH group levels in the liver and kidney. Biometals both reduced and increased F- toxicity. Further research is needed before Se should be considered as a promising strategy for mitigating F- toxicity. © 2022 Jelena Radovanović, Biljana Antonijević, Katarina Baralić, Marijana Ćurčić, Danijela Đukić-Ćosić, Zorica Bulat, Dragana Javorac, Aleksandra Buha Đorđević, Jelena Kotur-Stevuljević, Emina Sudar-Milovanović, Evica Antonijević Miljaković, Miloš Beloica, and Zoran Mandinić, published by Sciendo.  Cilj ovog istraživanja bio je utvrditi djelovanje 150 mg/L natrijevog fluorida (NaF) na redoks-status i koncentracije esencijalnih elemenata [bakar (Cu), željezo (Fe) i cink (Zn)] u krvi, jetri, bubrezima, mozgu i slezeni Wistar štakora te mogući zaštitni učinak selena (Se) od toksičnosti prouzročene fluoridom (F-). Mužjaci Wistar štakora nasumično su razvrstani u četiri skupine (n=5), nakon čega su 28 dana konzumirali običnu vodu ili vodu s otopinom NaF 150 mg/L, NaF 150 mg/L + Se 1,5 mg/L ili Se 1,5 mg/L. Izloženost fluoridu dovela je do poremećaja redoks-parametara i koncentracija istraživanih biometala. Utvrđene su povišene razine superoksid aniona (O2.-) i malondialdehida (MDA) u krvi i mozgu, smanjena aktivnost superoksid dismutaze (SOD1) u jetri te njezin porast u mozgu i bubrezima. Nadomjesni Se u kombinaciji s NaF pozitivno je utjecao na razine MDA, SOD1 i O2.- u krvi, mozgu i bubrezima, a sâm Se smanjio je razine SH skupina u jetri i bubrezima. Izloženost fluoridu uzrokovala je sniženje, ali i porast koncentracija biometala. Nužna su dodatna istraživanja kako bi se ispitali antioksidacijski učinci Se na toksičnost izazvanu F-.
T2  - Arhiv za higijenu rada i toksikologiju
T1  - Redox and biometal status in Wistar rats after subacute exposure to fluoride and selenium counter-effects
VL  - 73
IS  - 3
SP  - 207
EP  - 222
DO  - 10.2478/aiht-2022-73-3650
ER  - 

@article{
author = "Radovanović, Jelena and Antonijević, Biljana and Baralić, Katarina and Ćurčić, Marijana and Đukić-Ćosić, Danijela and Bulat, Zorica and Javorac, Dragana and Buha-Đorđević, Aleksandra and Kotur-Stevuljević, Jelena and Sudar-Milovanović, Emina and Antonijević-Miljaković, Evica and Beloica, Miloš and Mandinić, Zoran",
year = "2022",
abstract = "This study aimed to investigate the effect of 150 mg/L sodium fluoride (NaF) on redox status parameters and essential metals [copper (Cu), iron (Fe), and zinc (Zn)] in the blood, liver, kidney, brain, and spleen of Wistar rats and to determine the protective potential of selenium (Se) against fluoride (F-) toxicity. Male Wistar rats were randomly distributed in groups of five (n=5) receiving tap water (control) or water with NaF 150 mg/L, NaF 150 mg/L + Se 1.5 mg/L, and Se 1.5 mg/L solutions ad libitum for 28 days. Fluorides caused an imbalance in the redox and biometal (Cu, Fe, and Zn) status, leading to high superoxide anion (O2 .-) and malondialdehyde (MDA) levels in the blood and brain and a drop in superoxide dismutase (SOD1) activity in the liver and its increase in the brain and kidneys. Se given with NaF improved MDA, SOD1, and O2 .- in the blood, brain, and kidneys, while alone it decreased SH group levels in the liver and kidney. Biometals both reduced and increased F- toxicity. Further research is needed before Se should be considered as a promising strategy for mitigating F- toxicity. © 2022 Jelena Radovanović, Biljana Antonijević, Katarina Baralić, Marijana Ćurčić, Danijela Đukić-Ćosić, Zorica Bulat, Dragana Javorac, Aleksandra Buha Đorđević, Jelena Kotur-Stevuljević, Emina Sudar-Milovanović, Evica Antonijević Miljaković, Miloš Beloica, and Zoran Mandinić, published by Sciendo.  Cilj ovog istraživanja bio je utvrditi djelovanje 150 mg/L natrijevog fluorida (NaF) na redoks-status i koncentracije esencijalnih elemenata [bakar (Cu), željezo (Fe) i cink (Zn)] u krvi, jetri, bubrezima, mozgu i slezeni Wistar štakora te mogući zaštitni učinak selena (Se) od toksičnosti prouzročene fluoridom (F-). Mužjaci Wistar štakora nasumično su razvrstani u četiri skupine (n=5), nakon čega su 28 dana konzumirali običnu vodu ili vodu s otopinom NaF 150 mg/L, NaF 150 mg/L + Se 1,5 mg/L ili Se 1,5 mg/L. Izloženost fluoridu dovela je do poremećaja redoks-parametara i koncentracija istraživanih biometala. Utvrđene su povišene razine superoksid aniona (O2.-) i malondialdehida (MDA) u krvi i mozgu, smanjena aktivnost superoksid dismutaze (SOD1) u jetri te njezin porast u mozgu i bubrezima. Nadomjesni Se u kombinaciji s NaF pozitivno je utjecao na razine MDA, SOD1 i O2.- u krvi, mozgu i bubrezima, a sâm Se smanjio je razine SH skupina u jetri i bubrezima. Izloženost fluoridu uzrokovala je sniženje, ali i porast koncentracija biometala. Nužna su dodatna istraživanja kako bi se ispitali antioksidacijski učinci Se na toksičnost izazvanu F-.",
journal = "Arhiv za higijenu rada i toksikologiju",
title = "Redox and biometal status in Wistar rats after subacute exposure to fluoride and selenium counter-effects",
volume = "73",
number = "3",
pages = "207-222",
doi = "10.2478/aiht-2022-73-3650"
}

Radovanović, J., Antonijević, B., Baralić, K., Ćurčić, M., Đukić-Ćosić, D., Bulat, Z., Javorac, D., Buha-Đorđević, A., Kotur-Stevuljević, J., Sudar-Milovanović, E., Antonijević-Miljaković, E., Beloica, M.,& Mandinić, Z.. (2022). Redox and biometal status in Wistar rats after subacute exposure to fluoride and selenium counter-effects. in Arhiv za higijenu rada i toksikologiju, 73(3), 207-222.
https://doi.org/10.2478/aiht-2022-73-3650

Radovanović J, Antonijević B, Baralić K, Ćurčić M, Đukić-Ćosić D, Bulat Z, Javorac D, Buha-Đorđević A, Kotur-Stevuljević J, Sudar-Milovanović E, Antonijević-Miljaković E, Beloica M, Mandinić Z. Redox and biometal status in Wistar rats after subacute exposure to fluoride and selenium counter-effects. in Arhiv za higijenu rada i toksikologiju. 2022;73(3):207-222.
doi:10.2478/aiht-2022-73-3650 .

Radovanović, Jelena, Antonijević, Biljana, Baralić, Katarina, Ćurčić, Marijana, Đukić-Ćosić, Danijela, Bulat, Zorica, Javorac, Dragana, Buha-Đorđević, Aleksandra, Kotur-Stevuljević, Jelena, Sudar-Milovanović, Emina, Antonijević-Miljaković, Evica, Beloica, Miloš, Mandinić, Zoran, "Redox and biometal status in Wistar rats after subacute exposure to fluoride and selenium counter-effects" in Arhiv za higijenu rada i toksikologiju, 73, no. 3 (2022):207-222,
https://doi.org/10.2478/aiht-2022-73-3650 . .

TY  - JOUR
AU  - Jeremić, Ana
AU  - Miković, Željko
AU  - Sudar-Milovanović, Emina
AU  - Isenović, Esma R.
AU  - Perović, Milan
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9971
AB  - Follicular and serum vitamin D are considered potential markers of the oocyte and embryos' quality and predictors of IVF outcomes.   Material and methods:  This retrospective cross-sectional study correlated vitamin D in sera and follicular fluid of women with unexplained...
T2  - Archives of Medical Science
T1  - Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with in vitro fertilization outcome: an observational pilot study
VL  - 17
IS  - 5
SP  - 1418
EP  - 1422
DO  - 10.5114/aoms/141185
ER  - 

@article{
author = "Jeremić, Ana and Miković, Željko and Sudar-Milovanović, Emina and Isenović, Esma R. and Perović, Milan",
year = "2021",
abstract = "Follicular and serum vitamin D are considered potential markers of the oocyte and embryos' quality and predictors of IVF outcomes.   Material and methods:  This retrospective cross-sectional study correlated vitamin D in sera and follicular fluid of women with unexplained...",
journal = "Archives of Medical Science",
title = "Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with in vitro fertilization outcome: an observational pilot study",
volume = "17",
number = "5",
pages = "1418-1422",
doi = "10.5114/aoms/141185"
}

Jeremić, A., Miković, Ž., Sudar-Milovanović, E., Isenović, E. R.,& Perović, M.. (2021). Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with in vitro fertilization outcome: an observational pilot study. in Archives of Medical Science, 17(5), 1418-1422.
https://doi.org/10.5114/aoms/141185

Jeremić A, Miković Ž, Sudar-Milovanović E, Isenović ER, Perović M. Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with in vitro fertilization outcome: an observational pilot study. in Archives of Medical Science. 2021;17(5):1418-1422.
doi:10.5114/aoms/141185 .

Jeremić, Ana, Miković, Željko, Sudar-Milovanović, Emina, Isenović, Esma R., Perović, Milan, "Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with in vitro fertilization outcome: an observational pilot study" in Archives of Medical Science, 17, no. 5 (2021):1418-1422,
https://doi.org/10.5114/aoms/141185 . .

TY  - JOUR
AU  - Joksić, Gordana
AU  - Radak, Đorđe J.
AU  - Sudar-Milovanović, Emina
AU  - Obradović, Milan M.
AU  - Radovanović, Jelena V.
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9407
AB  - Background: Gentiana lutea (GL), commonly known as yellow gentian, bitter root, and bit-terwort, belongs to family Gentianaceae. GL belongs to genus Gentiana, which is a rich natural source of iridoids, secoiridoids, xantones, flavonoids, triterpenoids, and carbohydrates. Medicinal plants from Gentiana species have anti-oxidant, anti-inflammatory, anti-mitogenic, anti-proliferative, and lipid-lowering effects, as well as a cardioprotective, hypotensive, vasodilator and anti-platelet activities. Objective: We reviewed the recent literature related to the effects of Gentiana species, and their active components on vascular diseases. Methods: Data used for this review were obtained by searching the electronic database [PUB-MED/MEDLINE 1973-February 2020]. The primary data search terms of interest were: Gentiana lutea, Gentienacea family, phytochemistry, vascular diseases, treatment of vascular diseases, anti-oxidant, anti-inflammatory, anti-atherogenic. Conclusion: Gentiana species and their constituents affect many different factors related to vascular disease development and progression. Therefore, Gentiana-based therapeutics represent potentially use-ful drugs for the management of vascular diseases. © 2021 Bentham Science Publishers.
T2  - Current Vascular Pharmacology
T1  - Effects of Gentiana lutea Root on Vascular Diseases
VL  - 19
IS  - 4
SP  - 359
EP  - 369
DO  - 10.2174/1570161118666200529111314
ER  - 

@article{
author = "Joksić, Gordana and Radak, Đorđe J. and Sudar-Milovanović, Emina and Obradović, Milan M. and Radovanović, Jelena V. and Isenović, Esma R.",
year = "2021",
abstract = "Background: Gentiana lutea (GL), commonly known as yellow gentian, bitter root, and bit-terwort, belongs to family Gentianaceae. GL belongs to genus Gentiana, which is a rich natural source of iridoids, secoiridoids, xantones, flavonoids, triterpenoids, and carbohydrates. Medicinal plants from Gentiana species have anti-oxidant, anti-inflammatory, anti-mitogenic, anti-proliferative, and lipid-lowering effects, as well as a cardioprotective, hypotensive, vasodilator and anti-platelet activities. Objective: We reviewed the recent literature related to the effects of Gentiana species, and their active components on vascular diseases. Methods: Data used for this review were obtained by searching the electronic database [PUB-MED/MEDLINE 1973-February 2020]. The primary data search terms of interest were: Gentiana lutea, Gentienacea family, phytochemistry, vascular diseases, treatment of vascular diseases, anti-oxidant, anti-inflammatory, anti-atherogenic. Conclusion: Gentiana species and their constituents affect many different factors related to vascular disease development and progression. Therefore, Gentiana-based therapeutics represent potentially use-ful drugs for the management of vascular diseases. © 2021 Bentham Science Publishers.",
journal = "Current Vascular Pharmacology",
title = "Effects of Gentiana lutea Root on Vascular Diseases",
volume = "19",
number = "4",
pages = "359-369",
doi = "10.2174/1570161118666200529111314"
}

Joksić, G., Radak, Đ. J., Sudar-Milovanović, E., Obradović, M. M., Radovanović, J. V.,& Isenović, E. R.. (2021). Effects of Gentiana lutea Root on Vascular Diseases. in Current Vascular Pharmacology, 19(4), 359-369.
https://doi.org/10.2174/1570161118666200529111314

Joksić G, Radak ĐJ, Sudar-Milovanović E, Obradović MM, Radovanović JV, Isenović ER. Effects of Gentiana lutea Root on Vascular Diseases. in Current Vascular Pharmacology. 2021;19(4):359-369.
doi:10.2174/1570161118666200529111314 .

Joksić, Gordana, Radak, Đorđe J., Sudar-Milovanović, Emina, Obradović, Milan M., Radovanović, Jelena V., Isenović, Esma R., "Effects of Gentiana lutea Root on Vascular Diseases" in Current Vascular Pharmacology, 19, no. 4 (2021):359-369,
https://doi.org/10.2174/1570161118666200529111314 . .

TY  - CONF
AU  - Mitrović, Bojan
AU  - Samardžić, Vladimir
AU  - Gluvić, Zoran
AU  - Tomasević, Ratko
AU  - Obradović, Milan
AU  - Sudar-Milovanović, Emina
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12030
AB  - Introduction  Non-alcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome (MetS). Hence, it is frequently associated with type 2 diabetes mellitus (T2DM). The low-grade inflammation associated with NAFLD usually explained the changes in serum iron metabolism. This study aims to assess the link between liver steatosis severity and serum iron, ferritin, and transferrin levels.  Material and methods  A case-control study involved 30 non-obese subjects (BMI 18.5–30 kg/m2), who suffered from T2DM for less than 5 years. Such subjects are regularly under treatment by metformin (M) and sulphonylurea (SU) derivates. Liver steatosis severity is determined by ultrasonography and presented as grades 1, 2, and 3 (initial, moderate, and advanced liver steatosis), respectively, according to Singh et al. criteria (Singh et al. Indian J Endocr Metab 2013;17: 990–5).  Results  In the observed population, 14 (47%), 11 (36%), and 5 (17%) subjects are determined to grade 1, 2, and 3 liver steatosis severity groups, respectively. The mean values of iron homeostasis markers have not differed from normal values. Liver steatosis severity grades positively correlated with serum ferritin levels, and this correlation is not revealed in the cases with serum iron and transferrin levels.  Conclusion  The low grade of liver steatosis has predominated in non-obese T2DM subjects under treatment with M and SU, irrespective of glycemic control quality. An increase in liver steatosis severity follows the ascending trend of ferritin levels. Further studies are needed to elucidate the impact of the quality of T2DM control on liver steatosis severity and iron metabolism markers.
C3  - Endocrine Abstracts
T1  - Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD
DO  - 10.1530/endoabs.73.AEP294
ER  - 

@conference{
author = "Mitrović, Bojan and Samardžić, Vladimir and Gluvić, Zoran and Tomasević, Ratko and Obradović, Milan and Sudar-Milovanović, Emina and Isenović, Esma R.",
year = "2021",
abstract = "Introduction  Non-alcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome (MetS). Hence, it is frequently associated with type 2 diabetes mellitus (T2DM). The low-grade inflammation associated with NAFLD usually explained the changes in serum iron metabolism. This study aims to assess the link between liver steatosis severity and serum iron, ferritin, and transferrin levels.  Material and methods  A case-control study involved 30 non-obese subjects (BMI 18.5–30 kg/m2), who suffered from T2DM for less than 5 years. Such subjects are regularly under treatment by metformin (M) and sulphonylurea (SU) derivates. Liver steatosis severity is determined by ultrasonography and presented as grades 1, 2, and 3 (initial, moderate, and advanced liver steatosis), respectively, according to Singh et al. criteria (Singh et al. Indian J Endocr Metab 2013;17: 990–5).  Results  In the observed population, 14 (47%), 11 (36%), and 5 (17%) subjects are determined to grade 1, 2, and 3 liver steatosis severity groups, respectively. The mean values of iron homeostasis markers have not differed from normal values. Liver steatosis severity grades positively correlated with serum ferritin levels, and this correlation is not revealed in the cases with serum iron and transferrin levels.  Conclusion  The low grade of liver steatosis has predominated in non-obese T2DM subjects under treatment with M and SU, irrespective of glycemic control quality. An increase in liver steatosis severity follows the ascending trend of ferritin levels. Further studies are needed to elucidate the impact of the quality of T2DM control on liver steatosis severity and iron metabolism markers.",
journal = "Endocrine Abstracts",
title = "Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD",
doi = "10.1530/endoabs.73.AEP294"
}

Mitrović, B., Samardžić, V., Gluvić, Z., Tomasević, R., Obradović, M., Sudar-Milovanović, E.,& Isenović, E. R.. (2021). Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD. in Endocrine Abstracts.
https://doi.org/10.1530/endoabs.73.AEP294

Mitrović B, Samardžić V, Gluvić Z, Tomasević R, Obradović M, Sudar-Milovanović E, Isenović ER. Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD. in Endocrine Abstracts. 2021;.
doi:10.1530/endoabs.73.AEP294 .

Mitrović, Bojan, Samardžić, Vladimir, Gluvić, Zoran, Tomasević, Ratko, Obradović, Milan, Sudar-Milovanović, Emina, Isenović, Esma R., "Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD" in Endocrine Abstracts (2021),
https://doi.org/10.1530/endoabs.73.AEP294 . .

TY  - JOUR
AU  - Obradović, Milan
AU  - Sudar-Milovanović, Emina
AU  - Soskić, Sanja S.
AU  - Essack, Magbubah
AU  - Arya, Swati
AU  - Stewart, Alan J.
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9833
AB  - The peptide hormone leptin regulates food intake, body mass, and reproductive function and plays a role in fetal growth, proinflammatory immune responses, angiogenesis and lipolysis. Leptin is a product of the obese (ob) gene and, following synthesis and secretion from fat cells in white adipose tissue, binds to and activates its cognate receptor, the leptin receptor (LEP-R). LEP-R distribution facilitates leptin’s pleiotropic effects, playing a crucial role in regulating body mass via a negative feedback mechanism between adipose tissue and the hypothalamus. Leptin resistance is characterized by reduced satiety, over-consumption of nutrients, and increased total body mass. Often this leads to obesity, which reduces the effectiveness of using exogenous leptin as a therapeutic agent. Thus, combining leptin therapies with leptin sensitizers may help overcome such resistance and, consequently, obesity. This review examines recent data obtained from human and animal studies related to leptin, its role in obesity, and its usefulness in obesity treatment.
T2  - Frontiers in Endocrinology
T1  - Leptin and Obesity: Role and Clinical Implication
VL  - 12
SP  - 563
DO  - 10.3389/fendo.2021.585887
ER  - 

@article{
author = "Obradović, Milan and Sudar-Milovanović, Emina and Soskić, Sanja S. and Essack, Magbubah and Arya, Swati and Stewart, Alan J. and Gojobori, Takashi and Isenović, Esma R.",
year = "2021",
abstract = "The peptide hormone leptin regulates food intake, body mass, and reproductive function and plays a role in fetal growth, proinflammatory immune responses, angiogenesis and lipolysis. Leptin is a product of the obese (ob) gene and, following synthesis and secretion from fat cells in white adipose tissue, binds to and activates its cognate receptor, the leptin receptor (LEP-R). LEP-R distribution facilitates leptin’s pleiotropic effects, playing a crucial role in regulating body mass via a negative feedback mechanism between adipose tissue and the hypothalamus. Leptin resistance is characterized by reduced satiety, over-consumption of nutrients, and increased total body mass. Often this leads to obesity, which reduces the effectiveness of using exogenous leptin as a therapeutic agent. Thus, combining leptin therapies with leptin sensitizers may help overcome such resistance and, consequently, obesity. This review examines recent data obtained from human and animal studies related to leptin, its role in obesity, and its usefulness in obesity treatment.",
journal = "Frontiers in Endocrinology",
title = "Leptin and Obesity: Role and Clinical Implication",
volume = "12",
pages = "563",
doi = "10.3389/fendo.2021.585887"
}

Obradović, M., Sudar-Milovanović, E., Soskić, S. S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T.,& Isenović, E. R.. (2021). Leptin and Obesity: Role and Clinical Implication. in Frontiers in Endocrinology, 12, 563.
https://doi.org/10.3389/fendo.2021.585887

Obradović M, Sudar-Milovanović E, Soskić SS, Essack M, Arya S, Stewart AJ, Gojobori T, Isenović ER. Leptin and Obesity: Role and Clinical Implication. in Frontiers in Endocrinology. 2021;12:563.
doi:10.3389/fendo.2021.585887 .

Obradović, Milan, Sudar-Milovanović, Emina, Soskić, Sanja S., Essack, Magbubah, Arya, Swati, Stewart, Alan J., Gojobori, Takashi, Isenović, Esma R., "Leptin and Obesity: Role and Clinical Implication" in Frontiers in Endocrinology, 12 (2021):563,
https://doi.org/10.3389/fendo.2021.585887 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Zarić, Božidarka
AU  - Radovanović, Jelena V.
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Jevremović, Danimir
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9662
AB  - Vascular complications in patients with diabetes mellitus (DM) are common. Since impaired oxygen balance in plasma plays an important role in the pathogenesis of chronic DM-associated complications, the administration of hyperbaric oxygen therapy (HBOT) has been recommended to influence development of vascular complications. Hyperbaric oxygen therapy involves inhalation of 100% oxygen under elevated pressure from 1.6 to 2.8 absolute atmospheres in hyperbaric chambers. Hyperbaric oxygen therapy increases plasma oxygen solubility, contributing to better oxygen diffusion to distant tissues and preservation of the viability of tissues reversibly damaged by atherosclerosis-induced ischemia, along with microcirculation restoration. Hyperbaric oxygen therapy exerts antiatherogenic, antioxidant, and cardioprotective effects by altering the level and composition of plasma fatty acids and also by promoting signal transduction through membranes, which are impaired by hyperglycemia and hypoxia. In addition, HBOT affects molecules involved in the regulation of nitric oxide synthesis and in that way exerts anti-inflammatory and angiogenic effects in patients with DM. In this review, we explore the recent literature related to the effects of HBOT on DM-related vascular complications.
T2  - Angiology
T1  - Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus
VL  - 71
IS  - 10
SP  - 876
EP  - 885
DO  - 10.1177/0003319720936925
ER  - 

@article{
author = "Resanović, Ivana and Zarić, Božidarka and Radovanović, Jelena V. and Sudar-Milovanović, Emina and Gluvić, Zoran and Jevremović, Danimir and Isenović, Esma R.",
year = "2020",
abstract = "Vascular complications in patients with diabetes mellitus (DM) are common. Since impaired oxygen balance in plasma plays an important role in the pathogenesis of chronic DM-associated complications, the administration of hyperbaric oxygen therapy (HBOT) has been recommended to influence development of vascular complications. Hyperbaric oxygen therapy involves inhalation of 100% oxygen under elevated pressure from 1.6 to 2.8 absolute atmospheres in hyperbaric chambers. Hyperbaric oxygen therapy increases plasma oxygen solubility, contributing to better oxygen diffusion to distant tissues and preservation of the viability of tissues reversibly damaged by atherosclerosis-induced ischemia, along with microcirculation restoration. Hyperbaric oxygen therapy exerts antiatherogenic, antioxidant, and cardioprotective effects by altering the level and composition of plasma fatty acids and also by promoting signal transduction through membranes, which are impaired by hyperglycemia and hypoxia. In addition, HBOT affects molecules involved in the regulation of nitric oxide synthesis and in that way exerts anti-inflammatory and angiogenic effects in patients with DM. In this review, we explore the recent literature related to the effects of HBOT on DM-related vascular complications.",
journal = "Angiology",
title = "Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus",
volume = "71",
number = "10",
pages = "876-885",
doi = "10.1177/0003319720936925"
}

Resanović, I., Zarić, B., Radovanović, J. V., Sudar-Milovanović, E., Gluvić, Z., Jevremović, D.,& Isenović, E. R.. (2020). Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. in Angiology, 71(10), 876-885.
https://doi.org/10.1177/0003319720936925

Resanović I, Zarić B, Radovanović JV, Sudar-Milovanović E, Gluvić Z, Jevremović D, Isenović ER. Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. in Angiology. 2020;71(10):876-885.
doi:10.1177/0003319720936925 .

Resanović, Ivana, Zarić, Božidarka, Radovanović, Jelena V., Sudar-Milovanović, Emina, Gluvić, Zoran, Jevremović, Danimir, Isenović, Esma R., "Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus" in Angiology, 71, no. 10 (2020):876-885,
https://doi.org/10.1177/0003319720936925 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Zafirović, Sonja
AU  - Radak, Đorđe J.
AU  - Essack, Magbubah
AU  - Bajić, Vladimir B.
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8474
AB  - Hypothyroidism is a common endocrine disorder that predominantly occurs in females. It is associated with an increased risk of cardiovascular diseases (CVD), but the molecular mechanism is not known. Disturbance in lipid metabolism, the regulation of oxidative stress, and inflammation characterize the progression of subclinical hypothyroidism. The initiation and progression of endothelial dysfunction also exhibit these changes, which is the initial step in developing CVD. Animal and human studies highlight the critical role of nitric oxide (NO) as a reliable biomarker for cardiovascular risk in subclinical and clinical hypothyroidism. In this review, we summarize the recent literature findings associated with NO production by the thyroid hormones in both physiological and pathophysiological conditions. We also discuss the levothyroxine treatment effect on serum NO levels in hypothyroid patients. © 2020 The Authors
T2  - Biomedicine and Pharmacotherapy
T1  - Regulation of nitric oxide production in hypothyroidism
VL  - 124
SP  - 109881
DO  - 10.1016/j.biopha.2020.109881
ER  - 

@article{
author = "Gluvić, Zoran and Obradović, Milan M. and Sudar-Milovanović, Emina and Zafirović, Sonja and Radak, Đorđe J. and Essack, Magbubah and Bajić, Vladimir B. and Gojobori, Takashi and Isenović, Esma R.",
year = "2020",
abstract = "Hypothyroidism is a common endocrine disorder that predominantly occurs in females. It is associated with an increased risk of cardiovascular diseases (CVD), but the molecular mechanism is not known. Disturbance in lipid metabolism, the regulation of oxidative stress, and inflammation characterize the progression of subclinical hypothyroidism. The initiation and progression of endothelial dysfunction also exhibit these changes, which is the initial step in developing CVD. Animal and human studies highlight the critical role of nitric oxide (NO) as a reliable biomarker for cardiovascular risk in subclinical and clinical hypothyroidism. In this review, we summarize the recent literature findings associated with NO production by the thyroid hormones in both physiological and pathophysiological conditions. We also discuss the levothyroxine treatment effect on serum NO levels in hypothyroid patients. © 2020 The Authors",
journal = "Biomedicine and Pharmacotherapy",
title = "Regulation of nitric oxide production in hypothyroidism",
volume = "124",
pages = "109881",
doi = "10.1016/j.biopha.2020.109881"
}

Gluvić, Z., Obradović, M. M., Sudar-Milovanović, E., Zafirović, S., Radak, Đ. J., Essack, M., Bajić, V. B., Gojobori, T.,& Isenović, E. R.. (2020). Regulation of nitric oxide production in hypothyroidism. in Biomedicine and Pharmacotherapy, 124, 109881.
https://doi.org/10.1016/j.biopha.2020.109881

Gluvić Z, Obradović MM, Sudar-Milovanović E, Zafirović S, Radak ĐJ, Essack M, Bajić VB, Gojobori T, Isenović ER. Regulation of nitric oxide production in hypothyroidism. in Biomedicine and Pharmacotherapy. 2020;124:109881.
doi:10.1016/j.biopha.2020.109881 .

Gluvić, Zoran, Obradović, Milan M., Sudar-Milovanović, Emina, Zafirović, Sonja, Radak, Đorđe J., Essack, Magbubah, Bajić, Vladimir B., Gojobori, Takashi, Isenović, Esma R., "Regulation of nitric oxide production in hypothyroidism" in Biomedicine and Pharmacotherapy, 124 (2020):109881,
https://doi.org/10.1016/j.biopha.2020.109881 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Vučić, Vesna
AU  - Arsić, Aleksandra
AU  - Nedić, Olgica
AU  - Šunderić, Miloš
AU  - Gligorijević, Nikola
AU  - Milačić, Davorka
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8567
AB  - Objective: Metabolic changes in insulin-dependent diabetes mellitus (IDDM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in IDDM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in IDDM patients. Methods: Our study included 24 adult IDDM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis. Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT. Conclusions: Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition. © 2019 Canadian Diabetes Association
T2  - Canadian Journal of Diabetes
T1  - Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study
VL  - 44
IS  - 1
SP  - 22
EP  - 29
DO  - 10.1016/j.jcjd.2019.04.018
ER  - 

@article{
author = "Resanović, Ivana and Gluvić, Zoran and Zarić, Božidarka and Sudar-Milovanović, Emina and Vučić, Vesna and Arsić, Aleksandra and Nedić, Olgica and Šunderić, Miloš and Gligorijević, Nikola and Milačić, Davorka and Isenović, Esma R.",
year = "2020",
abstract = "Objective: Metabolic changes in insulin-dependent diabetes mellitus (IDDM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in IDDM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in IDDM patients. Methods: Our study included 24 adult IDDM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis. Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT. Conclusions: Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition. © 2019 Canadian Diabetes Association",
journal = "Canadian Journal of Diabetes",
title = "Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study",
volume = "44",
number = "1",
pages = "22-29",
doi = "10.1016/j.jcjd.2019.04.018"
}

Resanović, I., Gluvić, Z., Zarić, B., Sudar-Milovanović, E., Vučić, V., Arsić, A., Nedić, O., Šunderić, M., Gligorijević, N., Milačić, D.,& Isenović, E. R.. (2020). Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study. in Canadian Journal of Diabetes, 44(1), 22-29.
https://doi.org/10.1016/j.jcjd.2019.04.018

Resanović I, Gluvić Z, Zarić B, Sudar-Milovanović E, Vučić V, Arsić A, Nedić O, Šunderić M, Gligorijević N, Milačić D, Isenović ER. Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study. in Canadian Journal of Diabetes. 2020;44(1):22-29.
doi:10.1016/j.jcjd.2019.04.018 .

Resanović, Ivana, Gluvić, Zoran, Zarić, Božidarka, Sudar-Milovanović, Emina, Vučić, Vesna, Arsić, Aleksandra, Nedić, Olgica, Šunderić, Miloš, Gligorijević, Nikola, Milačić, Davorka, Isenović, Esma R., "Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study" in Canadian Journal of Diabetes, 44, no. 1 (2020):22-29,
https://doi.org/10.1016/j.jcjd.2019.04.018 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Essack, Magbubah
AU  - Zafirović, Sonja
AU  - Sudar-Milovanović, Emina
AU  - Bajić, Vladan P.
AU  - Van Neste, Christophe
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Bajić, Vladimir B.
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8486
AB  - Redox control is lost when the antioxidant defense system cannot remove abnormally high concentrations of signaling molecules, such as reactive oxygen species (ROS). Chronically elevated levels of ROS cause oxidative stress that may eventually lead to cancer and cardiovascular and neurodegenerative diseases. In this review, we focus on redox effects in the vascular system. We pay close attention to the subcompartments of the vascular system (endothelium, smooth muscle cell layer) and give an overview of how redox changes influence those different compartments. We also review the core aspects of redox biology, cardiovascular physiology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-RedoxVasc was used to develop two case studies, one focused on endothelial cells and the other on the vascular smooth muscle cells, as a starting point to possibly extend our knowledge of redox control in vascular biology. © 2019 The Authors. BioFactors published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology.
T2  - BioFactors
T1  - Redox control of vascular biology
VL  - 46
IS  - 2
SP  - 246
EP  - 262
DO  - 10.1002/biof.1559
ER  - 

@article{
author = "Obradović, Milan M. and Essack, Magbubah and Zafirović, Sonja and Sudar-Milovanović, Emina and Bajić, Vladan P. and Van Neste, Christophe and Trpković, Andreja and Stanimirović, Julijana and Bajić, Vladimir B. and Isenović, Esma R.",
year = "2020",
abstract = "Redox control is lost when the antioxidant defense system cannot remove abnormally high concentrations of signaling molecules, such as reactive oxygen species (ROS). Chronically elevated levels of ROS cause oxidative stress that may eventually lead to cancer and cardiovascular and neurodegenerative diseases. In this review, we focus on redox effects in the vascular system. We pay close attention to the subcompartments of the vascular system (endothelium, smooth muscle cell layer) and give an overview of how redox changes influence those different compartments. We also review the core aspects of redox biology, cardiovascular physiology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-RedoxVasc was used to develop two case studies, one focused on endothelial cells and the other on the vascular smooth muscle cells, as a starting point to possibly extend our knowledge of redox control in vascular biology. © 2019 The Authors. BioFactors published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology.",
journal = "BioFactors",
title = "Redox control of vascular biology",
volume = "46",
number = "2",
pages = "246-262",
doi = "10.1002/biof.1559"
}

Obradović, M. M., Essack, M., Zafirović, S., Sudar-Milovanović, E., Bajić, V. P., Van Neste, C., Trpković, A., Stanimirović, J., Bajić, V. B.,& Isenović, E. R.. (2020). Redox control of vascular biology. in BioFactors, 46(2), 246-262.
https://doi.org/10.1002/biof.1559

Obradović MM, Essack M, Zafirović S, Sudar-Milovanović E, Bajić VP, Van Neste C, Trpković A, Stanimirović J, Bajić VB, Isenović ER. Redox control of vascular biology. in BioFactors. 2020;46(2):246-262.
doi:10.1002/biof.1559 .

Obradović, Milan M., Essack, Magbubah, Zafirović, Sonja, Sudar-Milovanović, Emina, Bajić, Vladan P., Van Neste, Christophe, Trpković, Andreja, Stanimirović, Julijana, Bajić, Vladimir B., Isenović, Esma R., "Redox control of vascular biology" in BioFactors, 46, no. 2 (2020):246-262,
https://doi.org/10.1002/biof.1559 . .

TY  - JOUR
AU  - Zarić, Božidarka
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Nedeljković, Jovan
AU  - Lazić, Vesna M.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8378
AB  - Background: Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control. Objective: Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment. Results: Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin and minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location. Conclusions: The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. © 2019 Bentham Science Publishers.
T2  - Current Pharmaceutical Design
T1  - Drug Delivery Systems for Diabetes Treatment
VL  - 25
IS  - 2
SP  - 166
EP  - 173
DO  - 10.2174/1381612825666190306153838
ER  - 

@article{
author = "Zarić, Božidarka and Obradović, Milan M. and Sudar-Milovanović, Emina and Nedeljković, Jovan and Lazić, Vesna M. and Isenović, Esma R.",
year = "2019",
abstract = "Background: Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control. Objective: Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment. Results: Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin and minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location. Conclusions: The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. © 2019 Bentham Science Publishers.",
journal = "Current Pharmaceutical Design",
title = "Drug Delivery Systems for Diabetes Treatment",
volume = "25",
number = "2",
pages = "166-173",
doi = "10.2174/1381612825666190306153838"
}

Zarić, B., Obradović, M. M., Sudar-Milovanović, E., Nedeljković, J., Lazić, V. M.,& Isenović, E. R.. (2019). Drug Delivery Systems for Diabetes Treatment. in Current Pharmaceutical Design, 25(2), 166-173.
https://doi.org/10.2174/1381612825666190306153838

Zarić B, Obradović MM, Sudar-Milovanović E, Nedeljković J, Lazić VM, Isenović ER. Drug Delivery Systems for Diabetes Treatment. in Current Pharmaceutical Design. 2019;25(2):166-173.
doi:10.2174/1381612825666190306153838 .

Zarić, Božidarka, Obradović, Milan M., Sudar-Milovanović, Emina, Nedeljković, Jovan, Lazić, Vesna M., Isenović, Esma R., "Drug Delivery Systems for Diabetes Treatment" in Current Pharmaceutical Design, 25, no. 2 (2019):166-173,
https://doi.org/10.2174/1381612825666190306153838 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Jovanović, Aleksandra
AU  - Milačić, Davorka
AU  - Isaković, Radmilo
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://www.hindawi.com/journals/ije/2019/2328505/
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8209
AB  - This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor- κ B (NF κ B-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were significantly decreased ( p < 0.001 ). Protein expression of iNOS and serum nitrite/nitrate levels were decreased ( p < 0.01 ), while serum arginase activity was increased ( p < 0.05 ) versus before exposure to HBOT. Increased phosphorylation of NF κ B-p65 at Ser 536 ( p < 0.05 ) and decreased level of NF κ B-p65 protein ( p < 0.001 ) in lymphocytes of T1DM patients were observed after HBOT. Decreased phosphorylation of ERK1/2 ( p < 0.05 ) and Akt ( p < 0.05 ) was detected after HBOT. Our results indicate that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by decreased activity of NF κ B.
T2  - International Journal of Endocrinology
T1  - Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study
VL  - 2019
SP  - 1
EP  - 12
DO  - 10.1155/2019/2328505
ER  - 

@article{
author = "Resanović, Ivana and Gluvić, Zoran and Zarić, Božidarka and Sudar-Milovanović, Emina and Jovanović, Aleksandra and Milačić, Davorka and Isaković, Radmilo and Isenović, Esma R.",
year = "2019",
abstract = "This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor- κ B (NF κ B-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were significantly decreased ( p < 0.001 ). Protein expression of iNOS and serum nitrite/nitrate levels were decreased ( p < 0.01 ), while serum arginase activity was increased ( p < 0.05 ) versus before exposure to HBOT. Increased phosphorylation of NF κ B-p65 at Ser 536 ( p < 0.05 ) and decreased level of NF κ B-p65 protein ( p < 0.001 ) in lymphocytes of T1DM patients were observed after HBOT. Decreased phosphorylation of ERK1/2 ( p < 0.05 ) and Akt ( p < 0.05 ) was detected after HBOT. Our results indicate that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by decreased activity of NF κ B.",
journal = "International Journal of Endocrinology",
title = "Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study",
volume = "2019",
pages = "1-12",
doi = "10.1155/2019/2328505"
}

Resanović, I., Gluvić, Z., Zarić, B., Sudar-Milovanović, E., Jovanović, A., Milačić, D., Isaković, R.,& Isenović, E. R.. (2019). Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study. in International Journal of Endocrinology, 2019, 1-12.
https://doi.org/10.1155/2019/2328505

Resanović I, Gluvić Z, Zarić B, Sudar-Milovanović E, Jovanović A, Milačić D, Isaković R, Isenović ER. Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study. in International Journal of Endocrinology. 2019;2019:1-12.
doi:10.1155/2019/2328505 .

Resanović, Ivana, Gluvić, Zoran, Zarić, Božidarka, Sudar-Milovanović, Emina, Jovanović, Aleksandra, Milačić, Davorka, Isaković, Radmilo, Isenović, Esma R., "Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study" in International Journal of Endocrinology, 2019 (2019):1-12,
https://doi.org/10.1155/2019/2328505 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Sudar-Milovanović, Emina
AU  - Samardžić, Vladimir S.
AU  - Obradović, Milan M.
AU  - Jevremović, Danimir P.
AU  - Radenković, Saša P.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8369
AB  - Primary hypothyroidism can affect lipid metabolism, cardiovascular (CV) function, and overall patients’ quality of life (QoL). Decrease in serum nitric oxide (NO) levels could promote the atherosclerosis acceleration in hypothyroid patients. Our hypothesis is that serum NO level is altered in hypothyroidism; more specifically, we hypothesize that the early vascular changes that can be observed in hypothyroidism could be due to these alterations and that serum NO levels are associated with lipid levels in female patients diagnosed with subclinical hypothyroidism (SCH) or clinical hypothyroidism (CH). Furthermore, since serum NO level is an early marker of atherosclerosis and related CV disorders, which are commonly present and follow hypothyreosis and greatly contribute to overall QoL, we further hypothesized that NO level would correlate with Thyroid Symptom Questionnaire (TSQ) and General Health Questionnaire 12 (GHQ12) scores in hypothyroid patients. A collaterally of our hypothesis was that levothyroxine (LT4) treatment would affect serum NO levels as well as TSQ and GHQ12 scores. Therefore, we have analyzed lipid profile, the level of NO and QoL scores in female patients diagnosed with SCH and CH in order to determine the correlation between NO and generic and thyroid disease symptoms in treatment naïve SCH and CH patients and after LT4 treatment and laboratory euthyroidism achievement. As a consequence of our hypothesis is that measurement of serum NO level in SCH and CH patients may be an innovative way to improve LT4 treatment efficacy. This assumption could have a practical significance for future investigations regarding the management of hypothyroidism treatment protocols in current guidelines. © 2019 Elsevier Ltd
T2  - Medical Hypotheses
T1  - Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females
VL  - 131
SP  - 109299
DO  - 10.1016/j.mehy.2019.109299
ER  - 

@article{
author = "Gluvić, Zoran and Sudar-Milovanović, Emina and Samardžić, Vladimir S. and Obradović, Milan M. and Jevremović, Danimir P. and Radenković, Saša P. and Isenović, Esma R.",
year = "2019",
abstract = "Primary hypothyroidism can affect lipid metabolism, cardiovascular (CV) function, and overall patients’ quality of life (QoL). Decrease in serum nitric oxide (NO) levels could promote the atherosclerosis acceleration in hypothyroid patients. Our hypothesis is that serum NO level is altered in hypothyroidism; more specifically, we hypothesize that the early vascular changes that can be observed in hypothyroidism could be due to these alterations and that serum NO levels are associated with lipid levels in female patients diagnosed with subclinical hypothyroidism (SCH) or clinical hypothyroidism (CH). Furthermore, since serum NO level is an early marker of atherosclerosis and related CV disorders, which are commonly present and follow hypothyreosis and greatly contribute to overall QoL, we further hypothesized that NO level would correlate with Thyroid Symptom Questionnaire (TSQ) and General Health Questionnaire 12 (GHQ12) scores in hypothyroid patients. A collaterally of our hypothesis was that levothyroxine (LT4) treatment would affect serum NO levels as well as TSQ and GHQ12 scores. Therefore, we have analyzed lipid profile, the level of NO and QoL scores in female patients diagnosed with SCH and CH in order to determine the correlation between NO and generic and thyroid disease symptoms in treatment naïve SCH and CH patients and after LT4 treatment and laboratory euthyroidism achievement. As a consequence of our hypothesis is that measurement of serum NO level in SCH and CH patients may be an innovative way to improve LT4 treatment efficacy. This assumption could have a practical significance for future investigations regarding the management of hypothyroidism treatment protocols in current guidelines. © 2019 Elsevier Ltd",
journal = "Medical Hypotheses",
title = "Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females",
volume = "131",
pages = "109299",
doi = "10.1016/j.mehy.2019.109299"
}

Gluvić, Z., Sudar-Milovanović, E., Samardžić, V. S., Obradović, M. M., Jevremović, D. P., Radenković, S. P.,& Isenović, E. R.. (2019). Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females. in Medical Hypotheses, 131, 109299.
https://doi.org/10.1016/j.mehy.2019.109299

Gluvić Z, Sudar-Milovanović E, Samardžić VS, Obradović MM, Jevremović DP, Radenković SP, Isenović ER. Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females. in Medical Hypotheses. 2019;131:109299.
doi:10.1016/j.mehy.2019.109299 .

Gluvić, Zoran, Sudar-Milovanović, Emina, Samardžić, Vladimir S., Obradović, Milan M., Jevremović, Danimir P., Radenković, Saša P., Isenović, Esma R., "Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females" in Medical Hypotheses, 131 (2019):109299,
https://doi.org/10.1016/j.mehy.2019.109299 . .

TY  - JOUR
AU  - Zafirović, Sonja
AU  - Sudar-Milovanović, Emina
AU  - Obradović, Milan M.
AU  - Đorđević, Jelena D.
AU  - Jasnić, Nebojša
AU  - Labudović-Borović, Milica
AU  - Isenović, Esma R.
PY  - 2019
UR  - http://www.eurekaselect.com/159734/article
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8097
AB  - BACKGROUND: Oestradiol is an important regulatory factor with several positive effects on the cardiovascular (CV) system. We evaluated the molecular mechanism of the in vivo effects of oestradiol on the regulation of cardiac inducible nitric oxide (NO) synthase (iNOS) expression and activity. METHODS: Male Wistar rats were treated with oestradiol (40 mg/kg, intraperitoneally) and after 24 h the animals were sacrificed. The concentrations of NO and L-Arginine (L-Arg) were determined spectrophotometrically. For protein expressions of iNOS, p65 subunit of nuclear factor-κB (NFκB-p65), Ras homolog gene family-member A (RhoA), angiotensin II receptor type 1 (AT1R), insulin receptor substrate 1 (IRS-1), p85, p110 and protein kinase B (Akt), Western blot method was used. Coimmunoprecipitation was used for measuring the association of IRS-1 with the p85 subunit of phosphatidylinositol- 3-kinase (PI3K). The expression of iNOS messenger ribonucleic acid (mRNA) was measured with the quantitative real-time polymerase chain reaction (qRT-PCR). Immunohistochemical analysis of the tissue was used to detect localization and expression of iNOS in heart tissue. RESULTS: Oestradiol treatment reduced L-Arg concentration (p<0.01), iNOS mRNA (p<0.01) and protein (p<0.001) expression, level of RhoA (p<0.05) and AT1R (p<0.001) protein. In contrast, plasma NO (p<0.05), Akt phosphorylation at Thr308 (p<0.05) and protein level of p85 (p<0.001) increased after oestradiol treatment. CONCLUSION: Our results suggest that oestradiol in vivo regulates cardiac iNOS expression via the PI3K/Akt signaling pathway, through attenuation of RhoA and AT1R.
T2  - Current Vascular Pharmacology
T1  - Involvement of PI3K, Akt and RhoA in Oestradiol Regulation of Cardiac iNOS Expression
VL  - 17
IS  - 3
SP  - 307
EP  - 318
DO  - 10.2174/1570161116666180212142414
ER  - 

@article{
author = "Zafirović, Sonja and Sudar-Milovanović, Emina and Obradović, Milan M. and Đorđević, Jelena D. and Jasnić, Nebojša and Labudović-Borović, Milica and Isenović, Esma R.",
year = "2019",
abstract = "BACKGROUND: Oestradiol is an important regulatory factor with several positive effects on the cardiovascular (CV) system. We evaluated the molecular mechanism of the in vivo effects of oestradiol on the regulation of cardiac inducible nitric oxide (NO) synthase (iNOS) expression and activity. METHODS: Male Wistar rats were treated with oestradiol (40 mg/kg, intraperitoneally) and after 24 h the animals were sacrificed. The concentrations of NO and L-Arginine (L-Arg) were determined spectrophotometrically. For protein expressions of iNOS, p65 subunit of nuclear factor-κB (NFκB-p65), Ras homolog gene family-member A (RhoA), angiotensin II receptor type 1 (AT1R), insulin receptor substrate 1 (IRS-1), p85, p110 and protein kinase B (Akt), Western blot method was used. Coimmunoprecipitation was used for measuring the association of IRS-1 with the p85 subunit of phosphatidylinositol- 3-kinase (PI3K). The expression of iNOS messenger ribonucleic acid (mRNA) was measured with the quantitative real-time polymerase chain reaction (qRT-PCR). Immunohistochemical analysis of the tissue was used to detect localization and expression of iNOS in heart tissue. RESULTS: Oestradiol treatment reduced L-Arg concentration (p<0.01), iNOS mRNA (p<0.01) and protein (p<0.001) expression, level of RhoA (p<0.05) and AT1R (p<0.001) protein. In contrast, plasma NO (p<0.05), Akt phosphorylation at Thr308 (p<0.05) and protein level of p85 (p<0.001) increased after oestradiol treatment. CONCLUSION: Our results suggest that oestradiol in vivo regulates cardiac iNOS expression via the PI3K/Akt signaling pathway, through attenuation of RhoA and AT1R.",
journal = "Current Vascular Pharmacology",
title = "Involvement of PI3K, Akt and RhoA in Oestradiol Regulation of Cardiac iNOS Expression",
volume = "17",
number = "3",
pages = "307-318",
doi = "10.2174/1570161116666180212142414"
}

Zafirović, S., Sudar-Milovanović, E., Obradović, M. M., Đorđević, J. D., Jasnić, N., Labudović-Borović, M.,& Isenović, E. R.. (2019). Involvement of PI3K, Akt and RhoA in Oestradiol Regulation of Cardiac iNOS Expression. in Current Vascular Pharmacology, 17(3), 307-318.
https://doi.org/10.2174/1570161116666180212142414

Zafirović S, Sudar-Milovanović E, Obradović MM, Đorđević JD, Jasnić N, Labudović-Borović M, Isenović ER. Involvement of PI3K, Akt and RhoA in Oestradiol Regulation of Cardiac iNOS Expression. in Current Vascular Pharmacology. 2019;17(3):307-318.
doi:10.2174/1570161116666180212142414 .

Zafirović, Sonja, Sudar-Milovanović, Emina, Obradović, Milan M., Đorđević, Jelena D., Jasnić, Nebojša, Labudović-Borović, Milica, Isenović, Esma R., "Involvement of PI3K, Akt and RhoA in Oestradiol Regulation of Cardiac iNOS Expression" in Current Vascular Pharmacology, 17, no. 3 (2019):307-318,
https://doi.org/10.2174/1570161116666180212142414 . .

TY  - JOUR
AU  - Perović, Milan
AU  - Sudar-Milovanović, Emina
AU  - Simonović, Ema D.
AU  - Resanović, Ivana
AU  - Draganić, Veselin D.
AU  - Radaković, Jovana D.
AU  - Soldatović, Ivan A.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0306987718310892
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8006
AB  - Controlled ovarian stimulation (COS) is used to augment the number of retrieved oocytes in in vitro fertilization (IVF). Follicular fluid (FF) contributes significantly to oocyte quality. Since the FF is composed of follicular secretions and plasma exudation, it reflects alterations in granulosa and thecal cells secretion as well as changes in the level of plasma constituents. Phospholipids (PL) and free fatty acids (FFA) are important constituents of both, FF and serum. Our hypothesis is that COS affects the level of PL and FFA in serum. Furthermore, since the level of PL and FFA in FF partially depends on their levels in serum, as a collaterally of our hypothesis is that the existing level of PL and FFA in serum correlates with the levels of PL and FFA in FF, and that the dose of applied gonadotropins during COS will correlate with the levels of PL and FFA in serum and FF. In addition, we assume that the level of PL and FFA in serum and in FF after COS will correlate with the retrieved number of GQ oocytes, one of the most important outcomes of COS.. © 2018
T2  - Medical Hypotheses
T1  - Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation
VL  - 123
SP  - 30
EP  - 34
DO  - 10.1016/j.mehy.2018.11.021
ER  - 

@article{
author = "Perović, Milan and Sudar-Milovanović, Emina and Simonović, Ema D. and Resanović, Ivana and Draganić, Veselin D. and Radaković, Jovana D. and Soldatović, Ivan A. and Isenović, Esma R.",
year = "2019",
abstract = "Controlled ovarian stimulation (COS) is used to augment the number of retrieved oocytes in in vitro fertilization (IVF). Follicular fluid (FF) contributes significantly to oocyte quality. Since the FF is composed of follicular secretions and plasma exudation, it reflects alterations in granulosa and thecal cells secretion as well as changes in the level of plasma constituents. Phospholipids (PL) and free fatty acids (FFA) are important constituents of both, FF and serum. Our hypothesis is that COS affects the level of PL and FFA in serum. Furthermore, since the level of PL and FFA in FF partially depends on their levels in serum, as a collaterally of our hypothesis is that the existing level of PL and FFA in serum correlates with the levels of PL and FFA in FF, and that the dose of applied gonadotropins during COS will correlate with the levels of PL and FFA in serum and FF. In addition, we assume that the level of PL and FFA in serum and in FF after COS will correlate with the retrieved number of GQ oocytes, one of the most important outcomes of COS.. © 2018",
journal = "Medical Hypotheses",
title = "Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation",
volume = "123",
pages = "30-34",
doi = "10.1016/j.mehy.2018.11.021"
}

Perović, M., Sudar-Milovanović, E., Simonović, E. D., Resanović, I., Draganić, V. D., Radaković, J. D., Soldatović, I. A.,& Isenović, E. R.. (2019). Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation. in Medical Hypotheses, 123, 30-34.
https://doi.org/10.1016/j.mehy.2018.11.021

Perović M, Sudar-Milovanović E, Simonović ED, Resanović I, Draganić VD, Radaković JD, Soldatović IA, Isenović ER. Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation. in Medical Hypotheses. 2019;123:30-34.
doi:10.1016/j.mehy.2018.11.021 .

Perović, Milan, Sudar-Milovanović, Emina, Simonović, Ema D., Resanović, Ivana, Draganić, Veselin D., Radaković, Jovana D., Soldatović, Ivan A., Isenović, Esma R., "Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation" in Medical Hypotheses, 123 (2019):30-34,
https://doi.org/10.1016/j.mehy.2018.11.021 . .

TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Zarić, Božidarka
AU  - Đurić, Ilona
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2018
UR  - http://www.mdpi.com/1010-660X/54/3/36
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7878
AB  - Coronary artery disease (CAD) and myocardial infarction (MI) are recognized as leading causes of mortality in developed countries. Although typically associated with behavioral risk factors, such as smoking, sedentary lifestyle, and poor dietary habits, such vascular phenotypes have also long been recognized as being related to genetic background. We review the currently available data concerning genetic markers for CAD in English and non-English articles with English abstracts published between 2003 and 2018. As genetic testing is increasingly available, it may be possible to identify adequate genetic markers representing the risk profile and to use them in a clinical setting. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
T2  - Medicina
T1  - Genetic Markers for Coronary Artery Disease
VL  - 54
IS  - 3
SP  - 36
DO  - 10.3390/medicina54030036
ER  - 

@article{
author = "Veljković, Nevena V. and Zarić, Božidarka and Đurić, Ilona and Obradović, Milan M. and Sudar-Milovanović, Emina and Radak, Đorđe J. and Isenović, Esma R.",
year = "2018",
abstract = "Coronary artery disease (CAD) and myocardial infarction (MI) are recognized as leading causes of mortality in developed countries. Although typically associated with behavioral risk factors, such as smoking, sedentary lifestyle, and poor dietary habits, such vascular phenotypes have also long been recognized as being related to genetic background. We review the currently available data concerning genetic markers for CAD in English and non-English articles with English abstracts published between 2003 and 2018. As genetic testing is increasingly available, it may be possible to identify adequate genetic markers representing the risk profile and to use them in a clinical setting. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.",
journal = "Medicina",
title = "Genetic Markers for Coronary Artery Disease",
volume = "54",
number = "3",
pages = "36",
doi = "10.3390/medicina54030036"
}

Veljković, N. V., Zarić, B., Đurić, I., Obradović, M. M., Sudar-Milovanović, E., Radak, Đ. J.,& Isenović, E. R.. (2018). Genetic Markers for Coronary Artery Disease. in Medicina, 54(3), 36.
https://doi.org/10.3390/medicina54030036

Veljković NV, Zarić B, Đurić I, Obradović MM, Sudar-Milovanović E, Radak ĐJ, Isenović ER. Genetic Markers for Coronary Artery Disease. in Medicina. 2018;54(3):36.
doi:10.3390/medicina54030036 .

Veljković, Nevena V., Zarić, Božidarka, Đurić, Ilona, Obradović, Milan M., Sudar-Milovanović, Emina, Radak, Đorđe J., Isenović, Esma R., "Genetic Markers for Coronary Artery Disease" in Medicina, 54, no. 3 (2018):36,
https://doi.org/10.3390/medicina54030036 . .

TY  - JOUR
AU  - Panić, Anastasija
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Sudar-Milovanović, Emina
AU  - Petrović, Nina
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8013
AB  - 17β-Estradiol (E2) is known to negatively regulate inducible nitric oxide (NO) synthase (iNOS) expression via estrogen receptor alpha (ER-α) activation in aortic vascular smooth muscle cells.Therefore, we sought to determine whether E2 can inhibit iNOS in vivo in hepatic tissue via the activation of ER-α and whether extracellular signal-regulated kinases 1/2 (ERK1/2)-miR-221 axis is involved in this process. Male Wistar rats were treated with a bolus injection of E2 intraperitoneally (40 μg/kg), and 24 hours after treatment the animals were sacrificed and the livers excised. The protein levels of iNOS, p50 and p65 subunits of nuclear factor κB (NFκB), ERα, ERK1/2 and protein kinase B (Akt), as well as the association of ERα/Src in liver lysates were assessed by Western blot. The expression of hepatic miR-221 was analyzed by qRT-PCR. Results show that E2 reduced hepatic iNOS protein expression (p less than 0.01), the protein level of ERα (p less than 0.05), ERK1/2 (p less than 0.05), Akt phosphorylation (p less than 0.001) and miR-221 expression (p less than 0.05). In contrast, hepatic ERα/Src kinase association level (p less than 0.05) increased after E2 treatment. Our results indicate that E2 inhibits hepatic iNOS via molecular mechanisms involving the activation of the ER-α and inhibition of ERK1/2-miR-221 axis.
T2  - Journal of biological regulators and homeostatic agents
T1  - 17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis
VL  - 32
IS  - 6
SP  - 1369
EP  - 1377
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8013
ER  - 

@article{
author = "Panić, Anastasija and Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Sudar-Milovanović, Emina and Petrović, Nina and Isenović, Esma R.",
year = "2018",
abstract = "17β-Estradiol (E2) is known to negatively regulate inducible nitric oxide (NO) synthase (iNOS) expression via estrogen receptor alpha (ER-α) activation in aortic vascular smooth muscle cells.Therefore, we sought to determine whether E2 can inhibit iNOS in vivo in hepatic tissue via the activation of ER-α and whether extracellular signal-regulated kinases 1/2 (ERK1/2)-miR-221 axis is involved in this process. Male Wistar rats were treated with a bolus injection of E2 intraperitoneally (40 μg/kg), and 24 hours after treatment the animals were sacrificed and the livers excised. The protein levels of iNOS, p50 and p65 subunits of nuclear factor κB (NFκB), ERα, ERK1/2 and protein kinase B (Akt), as well as the association of ERα/Src in liver lysates were assessed by Western blot. The expression of hepatic miR-221 was analyzed by qRT-PCR. Results show that E2 reduced hepatic iNOS protein expression (p less than 0.01), the protein level of ERα (p less than 0.05), ERK1/2 (p less than 0.05), Akt phosphorylation (p less than 0.001) and miR-221 expression (p less than 0.05). In contrast, hepatic ERα/Src kinase association level (p less than 0.05) increased after E2 treatment. Our results indicate that E2 inhibits hepatic iNOS via molecular mechanisms involving the activation of the ER-α and inhibition of ERK1/2-miR-221 axis.",
journal = "Journal of biological regulators and homeostatic agents",
title = "17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis",
volume = "32",
number = "6",
pages = "1369-1377",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8013"
}

Panić, A., Stanimirović, J., Obradović, M. M., Zafirović, S., Sudar-Milovanović, E., Petrović, N.,& Isenović, E. R.. (2018). 17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis. in Journal of biological regulators and homeostatic agents, 32(6), 1369-1377.
https://hdl.handle.net/21.15107/rcub_vinar_8013

Panić A, Stanimirović J, Obradović MM, Zafirović S, Sudar-Milovanović E, Petrović N, Isenović ER. 17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis. in Journal of biological regulators and homeostatic agents. 2018;32(6):1369-1377.
https://hdl.handle.net/21.15107/rcub_vinar_8013 .

Panić, Anastasija, Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Sudar-Milovanović, Emina, Petrović, Nina, Isenović, Esma R., "17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis" in Journal of biological regulators and homeostatic agents, 32, no. 6 (2018):1369-1377,
https://hdl.handle.net/21.15107/rcub_vinar_8013 .

TY  - JOUR
AU  - Panić, Anastasija
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Perović, Milan
AU  - Lačković, Milena
AU  - Petrović, Nina
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8399
AB  - Purpose: This study aimed to investigate in vivo effects of estradiol on the regulation of hepatic inducible nitric oxide synthase (iNOS) expression in the high fat (HF) diet-induced obesity. Also, we aimed to investigate whether activation of the extracellular signal-regulated kinase (ERK1/2), adenosine monophosphate-activated protein kinase (AMPK), Src kinase, and miR-221 is involved in estradiol-mediated regulation of iNOS in the liver of obese male Wistar rats. Male Wistar rats were fed a standard laboratory diet or a HF diet for 10 weeks. Half of HF rats were treated with estradiol intraperitoneally (40 μg/kg), whereas the other half were placebo-treated 24 H before euthanasia. Results show that estradiol treatment of HF rats decreased hepatic iNOS mRNA (P < 0.05) and protein expression (P < 0.01), the protein levels of p65 subunit of nuclear factor κB (P < 0.05) and ERα (P < 0.05), ERK1/2 phosphorylation (P < 0.001), and ERα/Src kinase association (P < 0.05). By contrast, hepatic Src protein level (P < 0.05), AMPKα phosphorylation (P < 0.05), and miR-221 expression (P < 0.05) were increased in HF rats after estradiol treatment. Our results indicate that estradiol in vivo regulates hepatic iNOS expression in obese rats via molecular mechanisms involving ERK1/2, AMPK, Src, and miR-221 signaling. © 2018 International Union of Biochemistry and Molecular Biology, Inc.
T2  - Biotechnology and Applied Biochemistry
T1  - Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221
VL  - 65
IS  - 6
SP  - 797
EP  - 806
DO  - 10.1002/bab.1680
ER  - 

@article{
author = "Panić, Anastasija and Stanimirović, Julijana and Obradović, Milan M. and Sudar-Milovanović, Emina and Perović, Milan and Lačković, Milena and Petrović, Nina and Isenović, Esma R.",
year = "2018",
abstract = "Purpose: This study aimed to investigate in vivo effects of estradiol on the regulation of hepatic inducible nitric oxide synthase (iNOS) expression in the high fat (HF) diet-induced obesity. Also, we aimed to investigate whether activation of the extracellular signal-regulated kinase (ERK1/2), adenosine monophosphate-activated protein kinase (AMPK), Src kinase, and miR-221 is involved in estradiol-mediated regulation of iNOS in the liver of obese male Wistar rats. Male Wistar rats were fed a standard laboratory diet or a HF diet for 10 weeks. Half of HF rats were treated with estradiol intraperitoneally (40 μg/kg), whereas the other half were placebo-treated 24 H before euthanasia. Results show that estradiol treatment of HF rats decreased hepatic iNOS mRNA (P < 0.05) and protein expression (P < 0.01), the protein levels of p65 subunit of nuclear factor κB (P < 0.05) and ERα (P < 0.05), ERK1/2 phosphorylation (P < 0.001), and ERα/Src kinase association (P < 0.05). By contrast, hepatic Src protein level (P < 0.05), AMPKα phosphorylation (P < 0.05), and miR-221 expression (P < 0.05) were increased in HF rats after estradiol treatment. Our results indicate that estradiol in vivo regulates hepatic iNOS expression in obese rats via molecular mechanisms involving ERK1/2, AMPK, Src, and miR-221 signaling. © 2018 International Union of Biochemistry and Molecular Biology, Inc.",
journal = "Biotechnology and Applied Biochemistry",
title = "Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221",
volume = "65",
number = "6",
pages = "797-806",
doi = "10.1002/bab.1680"
}

Panić, A., Stanimirović, J., Obradović, M. M., Sudar-Milovanović, E., Perović, M., Lačković, M., Petrović, N.,& Isenović, E. R.. (2018). Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221. in Biotechnology and Applied Biochemistry, 65(6), 797-806.
https://doi.org/10.1002/bab.1680

Panić A, Stanimirović J, Obradović MM, Sudar-Milovanović E, Perović M, Lačković M, Petrović N, Isenović ER. Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221. in Biotechnology and Applied Biochemistry. 2018;65(6):797-806.
doi:10.1002/bab.1680 .

Panić, Anastasija, Stanimirović, Julijana, Obradović, Milan M., Sudar-Milovanović, Emina, Perović, Milan, Lačković, Milena, Petrović, Nina, Isenović, Esma R., "Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221" in Biotechnology and Applied Biochemistry, 65, no. 6 (2018):797-806,
https://doi.org/10.1002/bab.1680 . .

TY  - CHAP
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Perović, Milan
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8014
AB  - Nitric oxide (NO) is a free radical which, in reactions with various molecules causes multiple biological effects. NO is exceptionally regulated and extends to almost every cell type and function within circulation. Generation and actions of NO are regulated by various hormones under physiological and pathophysiological conditions. Nitric oxide synthases (NOS) are the enzymes responsible for NO generation. In mammals, neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while inducible NOS (iNOS) mediate in immune defense. Altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Disturbances in eNOS and iNOS regulation accompany multiple changes in endothelial function and contribute to development of CVD. Furthermore, key step in initiation and progression of atherosclerosis is reduction in bioactivity of endothelial cell-derived NO. Here we shall focus on recent literature data related to the role of eNOS and iNOS in physiological and pathophysiological conditions. © 2018 Nova Science Publishers, Inc. All rights reserved.
PB  - Nova Science Publishers
T2  - Horizons in World Cardiovascular Research
T1  - The role of eNOS and iNOS in pathophysiological conditions
VL  - 15
SP  - 65
EP  - 102
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8014
ER  - 

@inbook{
author = "Obradović, Milan M. and Zarić, Božidarka and Sudar-Milovanović, Emina and Perović, Milan and Resanović, Ivana and Gluvić, Zoran and Isenović, Esma R.",
year = "2018",
abstract = "Nitric oxide (NO) is a free radical which, in reactions with various molecules causes multiple biological effects. NO is exceptionally regulated and extends to almost every cell type and function within circulation. Generation and actions of NO are regulated by various hormones under physiological and pathophysiological conditions. Nitric oxide synthases (NOS) are the enzymes responsible for NO generation. In mammals, neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while inducible NOS (iNOS) mediate in immune defense. Altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Disturbances in eNOS and iNOS regulation accompany multiple changes in endothelial function and contribute to development of CVD. Furthermore, key step in initiation and progression of atherosclerosis is reduction in bioactivity of endothelial cell-derived NO. Here we shall focus on recent literature data related to the role of eNOS and iNOS in physiological and pathophysiological conditions. © 2018 Nova Science Publishers, Inc. All rights reserved.",
publisher = "Nova Science Publishers",
journal = "Horizons in World Cardiovascular Research",
booktitle = "The role of eNOS and iNOS in pathophysiological conditions",
volume = "15",
pages = "65-102",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8014"
}

Obradović, M. M., Zarić, B., Sudar-Milovanović, E., Perović, M., Resanović, I., Gluvić, Z.,& Isenović, E. R.. (2018). The role of eNOS and iNOS in pathophysiological conditions. in Horizons in World Cardiovascular Research
Nova Science Publishers., 15, 65-102.
https://hdl.handle.net/21.15107/rcub_vinar_8014

Obradović MM, Zarić B, Sudar-Milovanović E, Perović M, Resanović I, Gluvić Z, Isenović ER. The role of eNOS and iNOS in pathophysiological conditions. in Horizons in World Cardiovascular Research. 2018;15:65-102.
https://hdl.handle.net/21.15107/rcub_vinar_8014 .

Obradović, Milan M., Zarić, Božidarka, Sudar-Milovanović, Emina, Perović, Milan, Resanović, Ivana, Gluvić, Zoran, Isenović, Esma R., "The role of eNOS and iNOS in pathophysiological conditions" in Horizons in World Cardiovascular Research, 15 (2018):65-102,
https://hdl.handle.net/21.15107/rcub_vinar_8014 .

TY  - CONF
AU  - Panić, Anastasija
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0021915018307135
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7944
C3  - Atherosclerosis
T1  - IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway
VL  - 275
SP  - e137
DO  - 10.1016/j.atherosclerosis.2018.06.401
ER  - 

@conference{
author = "Panić, Anastasija and Stanimirović, Julijana and Obradović, Milan M. and Sudar-Milovanović, Emina and Isenović, Esma R.",
year = "2018",
journal = "Atherosclerosis",
title = "IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway",
volume = "275",
pages = "e137",
doi = "10.1016/j.atherosclerosis.2018.06.401"
}

Panić, A., Stanimirović, J., Obradović, M. M., Sudar-Milovanović, E.,& Isenović, E. R.. (2018). IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway. in Atherosclerosis, 275, e137.
https://doi.org/10.1016/j.atherosclerosis.2018.06.401

Panić A, Stanimirović J, Obradović MM, Sudar-Milovanović E, Isenović ER. IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway. in Atherosclerosis. 2018;275:e137.
doi:10.1016/j.atherosclerosis.2018.06.401 .

Panić, Anastasija, Stanimirović, Julijana, Obradović, Milan M., Sudar-Milovanović, Emina, Isenović, Esma R., "IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway" in Atherosclerosis, 275 (2018):e137,
https://doi.org/10.1016/j.atherosclerosis.2018.06.401 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Ilinčić, Branislava
AU  - Stokić, Edita
AU  - Perović, Milan
AU  - Isenović, Esma R.
PY  - 2018
UR  - http://www.eurekaselect.com/158061/article
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7916
AB  - Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is costeffectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.
T2  - Current Drug Targets
T1  - PCSK9 and Hypercholesterolemia: Therapeutic Approach
VL  - 19
IS  - 9
SP  - 1058
EP  - 1067
DO  - 10.2174/1389450119666171205101401
ER  - 

@article{
author = "Obradović, Milan M. and Zarić, Božidarka and Sudar-Milovanović, Emina and Ilinčić, Branislava and Stokić, Edita and Perović, Milan and Isenović, Esma R.",
year = "2018",
abstract = "Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is costeffectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.",
journal = "Current Drug Targets",
title = "PCSK9 and Hypercholesterolemia: Therapeutic Approach",
volume = "19",
number = "9",
pages = "1058-1067",
doi = "10.2174/1389450119666171205101401"
}

Obradović, M. M., Zarić, B., Sudar-Milovanović, E., Ilinčić, B., Stokić, E., Perović, M.,& Isenović, E. R.. (2018). PCSK9 and Hypercholesterolemia: Therapeutic Approach. in Current Drug Targets, 19(9), 1058-1067.
https://doi.org/10.2174/1389450119666171205101401

Obradović MM, Zarić B, Sudar-Milovanović E, Ilinčić B, Stokić E, Perović M, Isenović ER. PCSK9 and Hypercholesterolemia: Therapeutic Approach. in Current Drug Targets. 2018;19(9):1058-1067.
doi:10.2174/1389450119666171205101401 .

Obradović, Milan M., Zarić, Božidarka, Sudar-Milovanović, Emina, Ilinčić, Branislava, Stokić, Edita, Perović, Milan, Isenović, Esma R., "PCSK9 and Hypercholesterolemia: Therapeutic Approach" in Current Drug Targets, 19, no. 9 (2018):1058-1067,
https://doi.org/10.2174/1389450119666171205101401 . .